Biogen Expects Total Rev To Increase By A Mid-Single Digit Percentage For 2026

What happened

Biogen reported third-quarter revenue of $2.80 billion, above the IBES estimate of $2.63 billion, and adjusted earnings per share of $2.62 versus an estimate of $1.99. Biogen said total revenue is expected to increase by a mid-single digit percentage for 2026.

Confirmed

Global impact / market context

Biogen's quarterly revenue and profit beat analyst estimates, which may support investor confidence in its current drug sales. The stated 2026 revenue growth expectation gives investors a forward view, while the forecast adjusted earnings range of $12.20 to $13.00 brackets the $12.36 IBES estimate.

Analyst inference

The results compare with analyst estimates from IBES, a widely used survey of forecasts. Beating those estimates can shape how investors judge Biogen's sales momentum, and the 2026 revenue and earnings outlook will be weighed against the $10.45 billion IBES revenue view.

Analyst inference

What to watch

1. Watch whether Biogen's total revenue rises by a mid-single digit percentage in 2026, as the company expects. Also track Leqembi in-market revenue, reported at $202 million in the third quarter. Confirmed
2. Track whether Biogen's adjusted earnings per share land within its $12.20 to $13.00 2026 outlook and how that compares with the $12.36 IBES estimate. Proposed
3. Watch whether future quarterly revenue and adjusted earnings per share continue to beat IBES estimates, which would show whether the third-quarter outperformance reflects a lasting trend. Analyst inference

Evidence

• Original source link unavailable